Galmed rises as it teams up to test brain cancer drug

Eocene

14/04/2026 12:39

** Shares of biotech firm Galmed Pharmaceuticals GLMD.O rise 6.2% to $0.81 premarket

** Co says it partnered with Tel Aviv University to test Aramchol for brain cancer that has spread from other parts of the body

** The cancers are linked to an inactive p53 gene, which normally helps stop damaged cells from turning cancerous; when inactive, tumors grow and spread faster - GLMD

** Co says new academic research shows these tumors depend on a protein called SCD1 to survive

** Galmed says it has developed an experimental version of Aramchol that can enter the brain and block SCD1, aiming to slow or stop tumor growth

** Early animal studies suggest the drug could work and they also support Galmed’s colorectal cancer research, where p53 changes are common - GLMD

** As of last close, stock up ~1% YTD

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))